Pulmozyme® (dornase alfa, recombinant)
When launched in 1994, Pulmozyme® was the first new therapeutic drug for the management of cystic fibrosis in over 30 years.
Pulmozyme significantly reduces the risk of serious respiratory tract infections requiring parenteral antibiotics, improves lung fuction and improves quality of life for cystic fibrosis patients.
Full Prescribing Information
Safety and prescribing information for the Health Care Professional
Patient Assistance Program
If a patient needs a medicine, he or she should be able to receive it, regardless of economic or insurance status. Therefore, all of Genentech's products are covered by the Genentech Assistance Program, except for PulmozymeŽ (dornase alfa, recombinant), which is covered by the Genentech Endowment for Cystic Fibrosis.
Please Note This Is For Informational Purposes Only
BEF does not sell any of the products in CF Treatments Section. |
